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Objectives The goal of this study was to assess the frequency and predictors of vascular closure
device (VCD) deployment failure, and its association with vascular complications of 3 commonly
used VCDs.
Background VCDs are commonly used following percutaneous coronary intervention on the basis
of studies demonstrating reduced time to ambulation, increased patient comfort, and possible re-
duction in vascular complications as compared with manual compression. However, limited data are
available on the frequency and predictors of VCD failure, and the association of deployment failure
with vascular complications.
Methods From a de-identiﬁed dataset provided by Massachusetts Department of Health,
23,813 consecutive interventional coronary procedures that used either a collagen plug–based
(n  18,533), a nitinol clip–based (n  2,284), or a suture-based (n  2,996) VCD between June
2005 and December 2007 were identiﬁed. The authors deﬁned VCD failure as unsuccessful
deployment or failure to achieve immediate access site hemostasis.
Results Among 23,813 procedures, the VCD failed in 781 (3.3%) procedures (2.1% of collagen plug–
based, 6.1% of suture-based, 9.5% of nitinol clip–based VCDs). Patients with VCD failure had an ex-
cess risk of “any” (7.7% vs. 2.8%; p  0.001), major (3.3% vs. 0.8%; p  0.001), or minor (5.8% vs.
2.1%; p  0.001) vascular complications compared with successful VCD deployment. In a propensity
score–adjusted analysis, when compared with collagen plug–based VCD (reference odds ratio
[OR]  1.0), nitinol clip–based VCD had 2-fold increased risk (OR: 2.0, 95% conﬁdence interval [CI]:
1.8 to 2.3, p  0.001) and suture-based VCD had 1.25-fold increased risk (OR: 1.25, 95% CI: 1.2 to 1.3,
p  0.001) for VCD failure. VCD failure was a signiﬁcant predictor of subsequent vascular complications
for both collagen plug–based VCD and nitinol clip–based VCD, but not for suture-based VCD.
Conclusions VCD failure rates vary depending upon the type of VCD used and are associated with
signiﬁcantly higher vascular complications as compared with deployment successes. (J Am Coll
Cardiol Intv 2012;5:837–44) © 2012 by the American College of Cardiology Foundation
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838Vascular closure devices (VCD) have been used with in-
creasing frequency in the management of femoral arterial
access following cardiac catheterization and coronary inter-
ventional procedures on the basis of demonstrated improve-
ment in patient comfort and reduced time to ambulation
(1–3). Although randomized clinical trial data are lacking to
show a clear advantage in reducing vascular complications
relative to manual or mechanical compression, recent reg-
istry studies indicate that VCDs may be an effective bleed-
ing avoidance strategy compared with manual compression
(4–8). Importantly, the rate of vascular complications
following VCD deployment varies substantially depending
See page 845
upon the type of VCD used, success of deployment of the
VCD, and other factors (7,9–11). Although successful
deployment of VCD has been shown in several series to
reduce the vascular complication rate, consequences of
VCD failure are not well defined (4,9,12–14).
The objective of this study was 2-fold. First, we sought to
evaluate the frequency of VCD failure in routine practice
settings and its association with
vascular complications following
the deployment of the most
commonly used VCDs (collagen
plug–based [Angio-Seal, St. Jude
Medical, St. Paul, Minnesota], ni-
tinol clip–based [StarClose, Abbott
Vascular, Redwood City, Califor-
nia], and suture-based [Perclose,
Abbott Vascular, Santa Clara, Cal-
ifornia] VCDs). Second, we wished to identify factors that
might predict VCD failure.
Methods
Study population and data collection. The Massachusetts
Department of Public Health angioplasty registry collects
detailed clinical data and inpatient outcome information for
all adults (18 years of age or older) who undergo coronary
intervention at all nonfederal acute care Massachusetts
inpatient facilities. Using a de-identified dataset from 22
hospitals in Massachusetts provided by the Massachusetts
Department of Public Health, we evaluated consecutive
interventional coronary procedures by femoral access be-
tween June 2005 and December 2007. Patients who re-
ceived either a collagen plug–based (Angio-Seal), a nitinol
clip–based (StarClose), or a suture-based (Perclose) VCD,
representing the 3 most commonly used VCDs, were
selected for the study. Patients who received other VCDs
(n  130) and those who required an intra-aortic balloon
pump (n  189) during the cardiac catheterization proce-
Abbreviations
and Acronyms
CI  confidence interval
OR  odds ratio
PCI  percutaneous
coronary intervention
VCD  vascular closure
devicedure were excluded from the study. The state-wide datasetis based on the American College of Cardiology–National
Cardiovascular Data Registry definitions and contained
clinical and procedural elements for each patient and
follow-up information for the occurrence of all in-hospital
complications (15–18).
Cardiac catheterization and VCD protocol. Percutaneous
coronary intervention (PCI) was performed according to
standard clinical practice. The registry provided information
on routine clinical care as delivered to all consecutive
patients treated with PCI. Periprocedural glycoprotein IIb/
IIIa inhibitors and bivalirudin were used at the discretion of
the treating physician. The decision to use a VCD, as well
as the type of VCD used, was also left to the operator’s
discretion. VCD failure was defined as unsuccessful deploy-
ment or failure to achieve hemostasis in the laboratory and
was captured prospectively in the registry.
Outcome measures. Patients were followed for the occur-
ence of in-hospital vascular complications as part of state-
andated clinical outcomes reporting. Vascular complica-
ions included groin bleeding (defined as blood loss at the
ccess site resulting in blood transfusion, increased length of
tay, or a drop in hemoglobin of 3 g/dl), large hematoma
size 10 cm), pseudoaneurysm (confirmed by arteriogra-
hy or ultrasonography), arteriovenous fistula (confirmed by
rteriography or ultrasonography), retroperitoneal hemor-
hage, limb ischemia (loss of peripheral pulse requiring
ascular or surgical evaluation), or any case requiring vascu-
ar access–related surgical intervention. Major vascular com-
lication was defined as any retroperitoneal hemorrhage,
imb ischemia, or any vascular access–related surgical inter-
ention. Minor vascular complication was defined as any
roin bleeding, hematoma (10 cm), pseudoaneurysm, or
rteriovenous fistula. “Any” vascular complication was de-
ned as the occurrence of either a major or a minor vascular
omplication.
Statistical analysis. Continuous variables are reported as
median (with interquartile range) and categorical variables
as total number (percentage in the group). The baseline
clinical and procedural characteristics of the patient groups
were compared using the chi-square test or Fisher exact test
for categorical variables. Normally distributed continuous
variables were compared using the Student t test. Non-
normally distributed continuous variables were compared
with either the Wilcoxon rank sum test (for 2 patient
groups) or the Kruskal-Wallis test (for 3 patient groups), for
which post hoc comparisons were performed using the
Wilcoxon rank sum test with Bonferroni correction. We
employed an overall significance level of 0.05 except where
correction was used. Statistical analysis was performed using
SAS version 9.2 (SAS Institute, Cary, North Carolina).
Univariate analysis was performed to determine the
clinical and procedural characteristics associated with VCD
failure and vascular complications. A multivariate model
was built to evaluate the determinants of VCD failure using
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839a generalized estimating equation (PROC GENMOD)—
for logistic regression with binomial family and logit link,
and an independent working correlation structure that
accounted for within-hospital clustering of patients. In
addition, we performed a sensitivity analysis of the deter-
minants of VCD failure by using an exchangeable correla-
tion structure in logistic regression. The model was built
using risk factors identified from published research or
considered by domain experts to potentially influence VCD
failure. This approach has been shown to achieve better
performance when compared with automated stepwise vari-
able selection methods (4,9,12,19). The following variables
were used in the multivariate model: age, body mass index,
female sex, hypertension, diabetes mellitus, peripheral vas-
cular disease, estimated glomerular filtration rate60 ml/min, left
ventricular ejection fraction 30%, glycoprotein inhibitor
use, bivalirudin use, right heart catheterization, fluoroscopic
time, emergent status of PCI, and clinical site.
Because of the significant difference in the key baseline
characteristics among the 3 VCD patient groups, we per-
formed a propensity score–adjusted sensitivity analysis to
evaluate the relationship between VCD choice and subse-
quent VCD failure and vascular complications. Propensity
score for VCD failure was estimated by using a nonparsi-
monious multivariable multinominal logistic regression
model, with variables selected based on literature review for
predictors of vascular complications as well as on domain
Table 1. Baseline Characteristics of Patients Who R
Variable
Collagen Plug–Ba
(n  18,53
Age, yrs 63 (54–7
Female 5,225 (28.2
BMI, kg/m2 28.7 (26–3
Diabetes mellitus 5,422 (29.3
Diabetes on insulin 1,652 (8.2%
History of renal insufﬁciency 833 (4.5%
Estimated GFR (MDRD), ml/min/1.73 m2 75.5 (61–8
Prior MI 4,753 (25.6
Congestive HF 1,597 (8.6%
Hypertension 13,918 (75.1
Hyperlipidemia 14,832 (80.1
PVD history 1,769 (9.5%
STEMI 3,257 (17.6
LV ejection fraction 30% 8,210 (44.3
GPI use 8,738 (47.2
Right heart catheterization 1,881 (10.2
Emergent PCI 3,563 (19.2
Fluoro time (min) 14.3 (9–23
Values are median (interquartile range) or n (%). The p values for conti
variables were calculated by the Fisher exact test.
BMIbodymass index; CABG coronary artery bypass grafting; GF
IQR interquartile range; LV left ventricle; MDRDModified Dietintervention; PVD peripheral vascular disease; STEMI ST-segment elevatiexpert opinion. The following variables were used to calcu-
late the propensity score: age, body mass index, female sex,
hypertension, diabetes mellitus, tobacco smoking, dyslipide-
mia, peripheral vascular disease, estimated glomerular filtration
rate, history of congestive heart failure, acute myocardial
infarction, left ventricular ejection fraction30%, glycoprotein
nhibitor use, bivalirudin use, right heart catheterization, fluo-
oscopic time, emergent status of PCI, and clinical site. The
ropensity score–adjusted risk of VCD failure and vascular
omplications was subsequently calculated using a generalized
stimating equation for logistic regression (PROC GEN-
OD).
There were 10 (0.04%) missing values for body mass
ndex and 972 (4%) missing values for estimated glomerular
ltration rate in the dataset. Missing values of these 2
ariables were managed by simple imputation of their
edian values.
esults
Among 23,813 procedures in the study cohort using 1 of the
studied VCD following PCI, 18,533 procedures (78%) used
a collagen plug–based VCD, 2,284 procedures (10%) used a
nitinol clip–based VCD, and 2,996 procedures (12%) used
a suture-based VCD deployment. VCD deployment was
successful in 23,032 procedures (96.7%), and VCD failure
occurred in 781 procedures (3.3%). The baseline character-
d Different VCDs
D Nitinol Clip–Based VCD
(n  2,284)
Suture-Based VCD
(n  2,996) p Value
62 (53–72) 61 (53–71) 0.001
650 (28.5%) 833 (27.8%) 0.86
28.4 (26–32) 28.5 (26–32) 0.001
627 (27.4%) 843 (28.1%) 0.12
178 (7.8%) 258 (8.6%) 0.19
70 (3.1%) 111 (3.7%) 0.001
77.8 (64–91) 76.6 (62–89) 0.02
613 (26.8%) 843 (28.1%) 0.01
177 (7.8%) 263 (8.8%) 0.34
1,683 (73.7%) 2,214 (73.9%) 0.16
1,830 (80.1%) 2,410 (80.4%) 0.88
174 (7.6%) 260 (8.7%) 0.01
351 (15.4%) 524 (17.5%) 0.03
788 (34.5%) 1,242 (41.5%) 0.001
923 (40.4%) 1,228 (41%) 0.001
105 (4.6%) 189 (6.3%) 0.001
447 (19.6%) 641 (21.4%) 0.02
15.1 (10–23) 14.5 (10–23) 0.001
ariables were calculated by the Kruskal-Wallis test and for categorical
merular filtration rate; GPIglycoprotein inhibitor; HFheart failure;
al Disease; MImyocardial infarction; PCI percutaneous coronaryeceive
sed VC
3)
3)
%)
3)
%)
)
)
9)
%)
)
%)
%)
)
%)
%)
%)
%)
%)
)
nuous v
Rglo
and Renon myocardial infarction; VCD vascular closure device.
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840istics of the patients receiving the 3 different VCDs are
provided in Table 1. After correction for multiple compar-
isons, patients who received a collagen plug–based VCD
were more likely to be older, to have higher body mass
index, to have lower estimated glomerular filtration rate,
and required lesser fluoroscopic time compared with pa-
tients who received a nitinol clip–based VCD. Baseline
characteristics of patients who had successful versus unsuc-
cessful VCD deployment are provided in the Online Ap-
pendix (Online Table 1) Patients who had VCD failure
were more likely to be female, to have presented with
ST-segment elevation myocardial infarction, to have re-
ceived glycoprotein inhibitor, and to undergo emergent
PCI. VCD failure was less common in patients who were
hypertensive, had impaired left ventricular ejection fraction
30%, and who received drug-eluting stents.
VCD deployment failure. Overall, VCDs failed in 781 pro-
edures (3.3%). Collagen plug–based VCD had the lowest
CD failure rate of 2.1%, sutured-based VCD had a VCD
ailure rate of 6.1%, and nitinol clip–based VCD had the
ighest VCD failure rate of 9.5% (Table 2, Fig. 1).
ultivariable predictors of VCD failure included body mass
Table 2. Vascular Outcomes Stratified by the Type of VCD and Deployment
Variable
Collagen Plug–Based VCD (n  18,533)
VCD Success
(n  18,153)
VCD Failure
(n  380)
(2.1%) p Value
VC
(n
Any vascular complication 529 (2.9) 41 (10.8) 0.001
Major vascular complication 170 (0.9) 21 (5.5) 0.001
Minor vascular complication 395 (2.2) 28 (7.4) 0.001
Values are n (%). The p values were calculated by the Fisher exact test.
VCD vascular closure device.
Figure 1. Deployment Failure Rates of Different VCDs
A vertical bar graph showing deployment failure rates of the 3 vascularn
closure devices (VCDs).ndex, female sex, use of a glycoprotein inhibitor, use of
ivalirudin, hypertension, peripheral vascular disease, a high
stimated glomerular filtration rate, and those with left
entricular ejection 30% (Fig. 2). Sensitivity analysis
erformed by using an exchangeable correlation structure in
ogistic regression showed similar results. Propensity score–
djusted analysis of the impact of VCD choice on VCD
ailure demonstrated that compared with patients who
eceived a collagen plug–based VCD, patients who received
nitinol clip–based VCD had a 2-fold higher incidence of
CD failure (odds ratio [OR]: 2.0, 95% confidence interval
CI]: 1.8 to 2.1, p  0.001), and patients who received a
uture-based VCD had a 25% higher incidence of VCD
ailure (OR: 1.25, 95% CI: 1.2 to 1.3, p  0.001) (Table 3).
Vascular complications. Those patients in whom VCDs
ailed had significantly higher “any” (7.7% vs. 2.8%, p 
.001), major (3.3% vs. 0.8%, p  0.001), and minor (5.8%
s. 2.1%, p  0.001) vascular complications compared with
he group with successful deployment of VCD (Online
able 2). VCD failure and subsequent vascular complica-
ions were dependent upon the type of VCD used (Table 4,
ig. 3). In the unadjusted analysis, although the collagen
lug–based VCD had the lowest VCD failure rate, it had
he highest vascular complication rate in those patients who
ad VCD failure, compared with other VCDs. Although
he vascular complication rates were dependent upon the
uccess of deployment for the collagen plug–based VCD
nd nitinol clip–based VCD, the vascular complication
ates in the suture-based VCD were independent of the
uccess of that VCD.
Propensity analysis confirmed that VCD failure was a
ignificant predictor for vascular complications. Compared
ith patients who had successful deployment of a VCD,
ropensity analysis demonstrated that patients with VCD
ailure had, on average, a 3-fold higher incidence of any
ascular complication. Similarly, compared with patients
ho had successful deployment of VCDs, patients with
CD failure had a 5-fold higher incidence of a major
ascular complication and a 3-fold higher incidence of a
inor vascular complication. Vascular complications were
ess
l Clip–Based VCD (n  2,284) Suture-Based VCD (n  2,996)
cess
67)
VCD Failure
(n  217)
(9.5%) p Value
VCD Success
(n  2,814)
VCD Failure
(n  185)
6.1% p Value
) 13 (6.0) 0.01 61 (2.2) 6 (3.3) 0.30
) 4 (1.8) 0.02 10 (0.4) 1 (0.5) 0.50
11 (5.1) 0.01 52 (1.9) 6 (3.3) 0.17Succ
Nitino
D Suc
 2,0
45 (2.2
8 (0.4
41 (2)ot significantly different between nitinol clip–based VCD
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841and collagen plug–based VCD. However, suture-based
VCD was noted to have a lower incidence of any (OR: 0.85,
95% CI: 0.77 to 0.95, p 0.003) and major (OR: 0.62, 95%
I: 0.48 to 0.80, p  0.001) vascular complications
Table 3) after propensity score adjustment.
iscussion
Using a high-quality, mandatory state-level clinical out-
comes database, this study assessed the frequency and
predictors of VCD failure and subsequent vascular compli-
Figure 2. Multivariable Predictors of VCD Failure
Multivariable predictors of vascular closure device failure with their associated
generalized estimating equation (GENMOD) procedure for logistic regression u
ratios (ORs) with 95% conﬁdence intervals (CIs) are plotted on a logarithmic ax
provided on the right side of the plot. BMI  body mass index; GFR  glome
fraction; PCI  percutaneous coronary intervention; VCD  vascular closure de
Table 3. Propensity Score–Adjusted Analysis of VCD Failure
and Vascular Complications
Variable OR (95% CI) p Value
VCD failure
Nitinol clip–based VCD vs. collagen plug–based VCD 2.00 (1.88–2.13) 0.001
Suture-based VCD vs. collagen plug–based VCD 1.25 (1.16–1.33) 0.001
Any vascular complication
Nitinol clip–based VCD vs. collagen plug–based VCD 0.91 (0.82–1.02) 0.11
Suture-based VCD vs. collagen plug–based VCD 0.85 (0.77–0.95) 0.001
VCD failure 3.27 (2.78–3.84) 0.001
Major vascular complication
Nitinol clip–based VCD vs. collagen plug–based VCD 0.79 (0.62–1.02) 0.07
Suture-based VCD vs. collagen plug–based VCD 0.62 (0.48–0.80) 0.001
VCD failure 5.44 (4.25–6.96) 0.001
Minor vascular complication
Nitinol clip–based VCD vs. collagen plug–based VCD 0.99 (0.88–1.12) 0.91
Suture-based VCD vs. collagen plug–based VCD 0.89 (0.79–0.99) 0.05
VCD failure 2.97 (2.47–3.58) 0.001
A propensity score–adjusted multivariable odds ratio (OR), 95% confidence intervals (CI), and p
valueswere calculated using a generalized estimating equation (GENMOD) procedure for logistic
regression in SAS statistical software.vVCD vascular closure device.cations of 3 commonly used VCDs. This analysis demon-
strated that the rates of VCD failure and vascular compli-
cations vary among different types of VCDs. Multiple
patient characteristics determine the success of VCD de-
ployment and subsequent vascular complications.
VCD failure. VCDs have been established as an effective
trategy following PCI to enable early patient ambulation
nd improve patient satisfaction and comfort related to the
voidance of prolonged sheath insertion and manual com-
ression (4,8,20,21). However, a small proportion of VCD
eployments fail. The reported failure rates for these devices
ary widely, from 1.5% to 20% in contemporary studies
9–11,22–28). Moreover, reported failure rates of VCDs
epend upon the type of VCD used. In our statewide PCI
ohort, the VCD failure rate was 3.3%, and the device-
pecific failure rate ranged from 2.1% to 9.5%. The relatively
igher failure rate of the nitinol clip–based VCD as
ompared with other VCDs may be partly explained by the
earning curve effect associated with the adoption of the
evice since its introduction in early 2006, whereas the other
CDs studied had been in use in routine practice for many
ears (29,30). Our findings regarding the failure rate for the
itinol clip–based VCD are similar to reported failure rates
ith nitinol clip–based VCDs (10,11). However, that some
f the independent predictors of VCD failure, such as a
istory of hypertension and low left ventricular ejection
raction (30%), were identified to be protective against
CD failure seems counterintuitive. It is also possible that
ase selection bias (due to the physician’s decision to choose
VCD or not) might be an important factor affecting VCD
ailure.
The results of this study show that VCD failure is
ssociated with significantly higher any, major, and minor
ratios with 95% conﬁdence intervals and p values were calculated using a
n independent working correlation structure in SAS statistical software. Odds
e nonlogarithmic values for odds ratios with 95% conﬁdence intervals are
ﬁltration rate; GPI  glycoprotein inhibitor; LV EF  left ventricular ejectionodds
sing a
is. Th
rularascular complications compared with the group with suc-
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842cessful VCD deployment. Even after adjustment for clinical
variables, the VCD failure group had a 3- to 5-fold increase
in the odds of having any, major, and minor vascular
complications compared with the group with successful
VCD deployment. Our findings support the results of the
single-center observational study that analyzed failure rates
of collagen plug–based and suture-based VCDs (9).
Inﬂuence of the type of VCD. We found varying failure rates
among different VCDs. Although the collagen plug–based
VCD showed the lowest failure rate (2.1%), when deploy-
ment was unsuccessful, it was associated with the highest
vascular complication rate as compared with unsuccessful
deployment of the suture-based or nitinol clip–based VCD.
Deployment failure of the suture-based VCD did not
impact the vascular complication rate as compared with its
successful deployment. This may be due, in part, to the
availability of a “bailout” mechanism with suture-based
VCDs in the event of deployment failure that permits
control of the arteriotomy site with sheath replacement or a
second attempt at closure with a VCD. However, we can
only hypothesize that the availability of a bailout mechanism
with suture-based VCDs in the event of failure of suture
capture could have contributed to the lack of impact of
deployment failure of the suture-based VCD on the vascular
complication rate. No bailout mechanism is readily available
for either the collagen plug–based or the nitinol clip–based
Table 4. Vascular Complications and Other Outcome
Variable
Collagen Plug–Based VC
(n  18,533)
Complications
Vascular bleeding 387 (2.1)
Bleeding at PCI site 178 (1.0)
Retroperitoneal bleeding 157 (0.85)
Vascular occlusion 11 (0.06)
Peripheral embolization 10 (0.05)
Vascular dissection 8 (0.04)
Pseudoaneurysm 28 (0.15)
AV ﬁstula 9 (0.05)
Treated pseudoaneurysm 16 (0.1)
Any vascular complication 570 (3.1)
Major vascular complication 191 (1.0)
Minor vascular complication 423 (2.3)
Other outcomes
Periprocedural MI 471 (2.5)
Stroke 43 (0.2)
Renal failure 52 (0.3)
Death 122 (0.7)
MACE 689 (3.7)
MACCE 719 (3.9)
Values are n (%). The p values were calculated by the Fisher exact test
AV arteriovenous; MACEmajor adverse cardiovascular events; M
as in Table 1.VCD. iWe compared the VCD failure rates of different VCDs
after propensity score adjustment for baseline risks of
vascular complications. Although the nitinol clip–based
VCD had a 2-fold increased risk of VCD failure compared
with the collagen plug–based VCD, there was no significant
difference in the risk of vascular complications between
nitinol clip–based and collagen plug–based VCDs, after
adjustment for propensity to use the device. In addition,
although there was no significant difference in the risk of
minor vascular complication rate among different VCDs
after propensity score adjustment for baseline risk factors
and VCD failure, there was a significantly decreased risk of
major vascular complication rates of suture-based VCDs
compared with collagen plug–based VCDs.
Study limitations. This study has the inherent limitations of
ll retrospective observational studies. Despite multivariate
djustment for clustering of patients within the clinical site
o address the issue of institutional policy regarding VCD
se, and use of propensity score adjustment for the risk of
CD failure and vascular complications, unmeasured con-
ounding may still exist. Specifically, detailed angiographic
nformation regarding the location of the access site and
resence of atherosclerosis was not available, although these
ariables are known to be powerful predictors of vascular access
ite complications (31,32). Operator-level information and the
perator’s experience in the use of VCD were not available. It
ifferent VCDs
itinol Clip–Based VCD
(n  2,284)
Suture-Based VCD
(n  2,996) p Value
20 (0.9) 33 (1.1) 0.001
16 (0.7) 11 (0.4) 0.001
8 (0.35) 5 (0.17) 0.001
1 (0.04) 3 (0.1) 0.64
0 2 (0.07) 0.67
2 (0.1) 2 (0.07) 0.43
4 (0.2) 1 (0.03) 0.22
0 0 0.58
3 (0.1) 1 (0.03) 0.44
58 (2.5) 67 (2.2) 0.02
12 (0.5) 11 (0.4) 0.001
52 (2.3) 58 (1.9) 0.49
52 (2.8) 81 (2.7) 0.62
3 (0.1) 7 (0.2) 0.71
11 (0.5) 14 (0.5) 0.10
15 (0.7) 21 (0.7) 0.90
77 (3.4) 117 (3.9) 0.59
78 (3.4) 123 (4.1) 0.42
major adverse cardiac and cerebrovascular events; other abbreviationss of D
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843deployment of VCDs, and such information might be useful to
address potential learning curve effects with the adoption of
new VCDs. In addition, we evaluated in-hospital outcomes
only, and hence, any differences in late complications between
devices were not available.
Conclusions
In contemporary practice, VCD failure is rare but is dependent
on specific device choice and patient characteristics. In general,
VCD deployment failure significantly increases the subsequent
risk of vascular complication rates. Optimizing operator tech-
nique and experience with a single type of VCD may help
minimize VCD failure rates and thereby improve vascular
outcomes especially for collagen plug–based and nitinol clip–
based VCDs. In this analysis, the suture-based VCD demon-
strated a lower risk of vascular complications when compared
with other VCDs, irrespective of the success of VCD deploy-
ment. Given the limitations of this retrospective analysis, this
finding must be interpreted cautiously and should be con-
firmed in future prospective studies.
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Figure 3. Vascular Complication Rates of Different VCDs
A bar graph comparing vascular complication rates of different vascular closur
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